Purpose of Review <p>The treatment of gastric cancer continues to evolve, particularly with the development of immunotherapy protocols. This review seeks to succinctly highlight these changes as is relevant to the practicing surgeon.</p> Recent Findings <p>Minimally invasive surgical technique has become more wide-spread concurrent to the development of immunotherapy protocols showing promise to treat this highly morbid disease.</p> Summary <p>Surgeon awareness of ongoing work into neoadjuvant, surgical, and adjuvant therapies is essential to achieving positive outcomes for patients diagnosed with gastric cancer as the surgeon serves a vital role in the multidisciplinary team.</p>